Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Change in Account Payables (2019 - 2025)

Benitec Biopharma's Change in Account Payables history spans 7 years, with the latest figure at $980000.0 for Q1 2025.

  • For Q1 2025, Change in Account Payables rose 142.44% year-over-year to $980000.0; the TTM value through Mar 2025 reached $1.5 million, up 781.71%, while the annual FY2024 figure was $941000.0, 30.66% down from the prior year.
  • Change in Account Payables for Q1 2025 was $980000.0 at Benitec Biopharma, up from -$658000.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $1.6 million in Q1 2021 and bottomed at -$2.3 million in Q1 2024.
  • The 5-year median for Change in Account Payables is $566000.0 (2023), against an average of $227647.1.
  • The largest annual shift saw Change in Account Payables soared 376.95% in 2021 before it crashed 466.51% in 2024.
  • A 5-year view of Change in Account Payables shows it stood at $853000.0 in 2021, then plummeted by 164.48% to -$550000.0 in 2022, then skyrocketed by 307.45% to $1.1 million in 2023, then plummeted by 157.67% to -$658000.0 in 2024, then skyrocketed by 248.94% to $980000.0 in 2025.
  • Per Business Quant, the three most recent readings for BNTC's Change in Account Payables are $980000.0 (Q1 2025), -$658000.0 (Q4 2024), and -$322000.0 (Q3 2024).